Company / Operating Cash Flow
Fulgent Genetics, Inc. Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$101.6M
FY2025
5-year range
-$101.6M / $538.6M
FY2021-FY2025
Trend
-582.6%
vs FY2024
Sector context
#157 of 164
Health Care
What the data says
Operating Cash Flow changed -583% YoY in FY2025, a notable deviation from the 9-year average annual change of +2541%.
Based on SEC 10-K filings.
-$102M in FY2025.
Declined from $539M to -$102M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 4% in Health CareTop 96% of 164This company -$101.6M Sector average $1.0B
▼
-109.7% below sector average
Key checks
Key Insights
- In FY2025, operating cash flow decreased 582.6% year-over-year.
- Ranks #157 out of 164 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score 5.28 (safe zone, above 2.9 threshold)
- Negative profit margin: -15.1%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$101.6M | -582.6% |
| FY2024 | $21.1M | -96.1% |
| FY2023 | $538.6M | +283.0% |
| FY2022 | $140.6M | +2449.0% |
| FY2021 | $5.5M | -96.1% |
| FY2020 | $140.6M | +20933.8% |
| FY2019 | -$675.0K | -150.7% |
| FY2018 | $1.3M | +0.0% |
| FY2017 | $1.3M | +130.3% |
| FY2016 | -$4.4M | -353.8% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026